Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0PW4N
|
|||
| Former ID |
DCL000139
|
|||
| Drug Name |
Ispinesib
|
|||
| Synonyms |
SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Head and neck cancer [ICD-11: 2D42] | Phase 2 | [1] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56] | Phase 2 | [1] | ||
| Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64] | Phase 2 | [1] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 2 | [1] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Cytokinetics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C30H33ClN4O2
|
|||
| Canonical SMILES |
CC1=CC=C(C=C1)C(=O)N(CCCN)C(C2=NC3=C(C=CC(=C3)Cl)C(=O)N2CC4=CC=CC=C4)C(C)C
|
|||
| InChI |
1S/C30H33ClN4O2/c1-20(2)27(34(17-7-16-32)29(36)23-12-10-21(3)11-13-23)28-33-26-18-24(31)14-15-25(26)30(37)35(28)19-22-8-5-4-6-9-22/h4-6,8-15,18,20,27H,7,16-17,19,32H2,1-3H3/t27-/m1/s1
|
|||
| InChIKey |
QJZRFPJCWMNVAV-HHHXNRCGSA-N
|
|||
| CAS Number |
CAS 336113-53-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14787129, 16297029, 23948567, 26683880, 43491186, 57371393, 74785572, 93580978, 99006911, 99437158, 103524102, 114686684, 124757259, 125164063, 126671564, 131480878, 134338821, 135252147, 136340273, 136367425, 136367912, 136920400, 137248935, 137276018, 140511365, 144116087, 144187399, 152188039, 152258826, 152344385, 160647677, 160861642, 162011777, 162037606, 164160766, 164761401, 174528958, 177748760, 185971559, 196409712, 198979359, 223668104, 224000297, 229586202, 242739181, 251971334, 252158830, 252161008, 252436535, 252451718
|
|||
| ChEBI ID |
CHEBI:94692
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Kinesin-like protein KIF11 (KIF11) | Target Info | Inhibitor | [2], [3], [4] |
| Reactome | MHC class II antigen presentation | |||
| Kinesins | ||||
| WikiPathways | MHC class II antigen presentation | |||
| Kinesins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00095628) SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009 Dec 15;53(7):1255-63. | |||
| REF 3 | KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain BMC Cancer. 2009 Jun 22;9:196. | |||
| REF 4 | Gateways to clinical trials. July-August 2008. Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):459-95. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.